×
About 2,013 results

ALLMedicine™ Allergic Conjunctivitis Center

Research & Reviews  317 results

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
https://clinicaltrials.gov/ct2/show/NCT05158972

Dec 15th, 2021 - A) Primary objective: Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice; Patient's demographic; Anamnestic background including: allergic and other comorbidities aller...

The relationship between allergic diseases and tic disorders: A systematic review and m...
https://doi.org/10.1016/j.neubiorev.2021.12.004
Neuroscience and Biobehavioral Reviews; Huang J, Li R et. al.

Dec 10th, 2021 - This systematic review aims to 1) explore the association between tic disorders (TD) and allergic diseases (AD), 2) judge whether patients with a diagnosis of TD are prone to suffer from a specific AD, by compiling the literature and analyzing the...

Kawasaki Disease and Atopic Diseases: A Systematic Review and Meta-Analysis of Observat...
https://doi.org/10.1159/000520045
International Archives of Allergy and Immunology; Wang Z, Zhang J et. al.

Nov 24th, 2021 - The etiology of Kawasaki disease (KD), an inflammatory and cardiovascular disorder, remains largely unexplained after more than 50 years of intensive research. In recent years, the association between KD and atopic diseases had been explored by so...

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
https://clinicaltrials.gov/ct2/show/NCT03231969

Nov 24th, 2021 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

Optimization of a histamine-induced allergic conjunctivitis model in Guinea pigs.
https://doi.org/10.1016/j.vascn.2021.107133
Journal of Pharmacological and Toxicological Methods; Mochizuki H, Suyama S et. al.

Nov 20th, 2021 - Allergic conjunctivitis is one of the most common immune diseases in the field of ophthalmology. The number of patients suffering from allergic conjunctivitis has been increasing, and there is still a strong need for development of therapeutic age...

see more →

Drugs  410 results see all →

Clinicaltrials.gov  38 results

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
https://clinicaltrials.gov/ct2/show/NCT05158972

Dec 15th, 2021 - A) Primary objective: Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice; Patient's demographic; Anamnestic background including: allergic and other comorbidities aller...

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
https://clinicaltrials.gov/ct2/show/NCT03231969

Nov 24th, 2021 - To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT04050865

Oct 7th, 2021 - The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
https://clinicaltrials.gov/ct2/show/NCT04198740

Aug 2nd, 2021 - This is an exploratory study. The investigators aim to: Test and perfect a tear sample analysis technique by mass spectrometry with samples collected by Schirmer strips; Obtain the lacrimal fingerprint for various pathologies of the ocular surface...

Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment
https://clinicaltrials.gov/ct2/show/NCT04776096

Apr 1st, 2021 - The present study will be carried out to evaluate the antiallergic efficacy of Bepotastine besilate 1.5% free of preservatives versus standard treatment with 0.2% Olopatadine hydrochloride with 0.1% benzalkonium chloride as preservative in adult p...

see more →

News  38 results

One in 15 Patients Who Start Dupilumab May Develop Conjunctivitis, Large Analysis Finds
https://www.medscape.com/viewarticle/953387

Jun 18th, 2021 - One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. "About 4 years after dupilumab's ap...

Allergic Conjunctivitis Severely Affects Children's Quality of Life
https://www.medscape.com/viewarticle/953091

Jun 15th, 2021 - Allergic conjunctivitis harms quality of life for children and their parents, apparently causing greater day-to-day worries than potentially blinding diseases, researchers report. Parents worry especially that treatments might not be effective, ac...

Epinephrine-Coated Syringes Curb Local Reactions to Immunotherapy
https://www.medscape.com/viewarticle/922769

Dec 18th, 2019 - NEW YORK (Reuters Health) - Using epinephrine-coated syringes for subcutaneous immunotherapy (SCIT) lowers the risk of local reactions such as erythema and swelling at injection sites, according to researchers in Thailand. Such syringes, Dr. Orath...

Fast Five Quiz: Allergy Triggers
https://reference.medscape.com/viewarticle/917113_4

Aug 23rd, 2019 - Immediate hypersensitivity skin testing is the most useful method to detect immunoglobulin E antibody against mold allergens. Testing can be performed by using the prick or intradermal method. The preferred sites are the upper part of the back for...

Eton's conjunctivitis treatment fails to win FDA nod; shares tumble
https://www.reuters.com/article/us-eton-pharms-fda/etons-conjunctivitis-treatment-fails-to-win-fda-nod-shares-tumble-idUSKCN1U72KP

Jul 12th, 2019 - (Reuters) - Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment for conjunctivitis, sending its shares tumbling nearly 20 percent in extended trading. No concerns were raised about t...

see more →

Patient Education  2 results see all →